MOTRIN MIGRAINE PAIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MOTRIN MIGRAINE PAIN (MOTRIN MIGRAINE PAIN).
Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.
| Metabolism | Primarily hepatic via CYP2C9; metabolites undergo glucuronidation and renal excretion. |
| Excretion | Renal: 90% (metabolites and unchanged, 10-20% unchanged). Biliary/Fecal: <5%. |
| Half-life | 2 hours (1.5-2.5 h in adults; prolonged in elderly and renal impairment). |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | 0.1-0.2 L/kg. Clinical meaning: Low Vd indicates limited tissue distribution, primarily in plasma. |
| Bioavailability | Oral: 80-100% (absolute bioavailability). |
| Onset of Action | Oral: 30-60 minutes for analgesia. Peak effect: 1-2 hours. |
| Duration of Action | 4-6 hours (oral). Clinical note: Duration is dose-dependent; higher doses may provide longer relief. |
Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: No adjustment; eGFR 15-29 mL/min: Reduce dose to 200 mg every 6-8 hours, maximum 600 mg/day; eGFR <15 mL/min: Avoid use. |
| Liver impairment | Child-Pugh Class A: No adjustment; Child-Pugh Class B: Use with caution, reduce dose by 50%; Child-Pugh Class C: Avoid use. |
| Pediatric use | Children weighing ≥50 kg: Same as adult; <50 kg: 7.5-10 mg/kg per dose every 6-8 hours, maximum 30 mg/kg/day. |
| Geriatric use | Start at lowest effective dose (200 mg every 6-8 hours), monitor renal function and gastrointestinal bleeding risk; maximum 600 mg/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MOTRIN MIGRAINE PAIN (MOTRIN MIGRAINE PAIN).
| Breastfeeding | Ibuprofen is excreted into breast milk in low amounts (M/P ratio approximately 0.6-1.0). Peak infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; use lowest effective dose for shortest duration. |
| Teratogenic Risk | First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated after 30 weeks gestation due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. NSAID use after 20 weeks may cause oligohydramnios from fetal renal dysfunction. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
| Serious Effects |
Known hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; late pregnancy (third trimester).
| Precautions | Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke; risk of serious GI adverse events; avoid in setting of coronary artery bypass graft (CABG) surgery; renal toxicity; anaphylactoid reactions; severe skin reactions (e.g., Stevens-Johnson syndrome); may blunt the antihypertensive effect of ACE inhibitors; avoid late pregnancy due to risk of premature closure of ductus arteriosus. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and signs of bleeding. Fetal ultrasound to assess amniotic fluid volume if used for >48 hours after 20 weeks gestation. Doppler assessment of ductus arteriosus if used after 30 weeks. |
| Fertility Effects | Reversible inhibition of prostaglandin synthesis may impair ovulation and implantation. Use may delay conception; effects resolve upon discontinuation. Consider in women with unexplained infertility. |